Krystal Biotech Inc (KRYS)

Jan 14, 2025, 8:00 AM EST - 3 days ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Dec 27, 2024, 8:30 AM EST - 21 days ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 18, 2024, 8:00 AM EST - 4 weeks ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 9, 2024, 4:15 PM EST - 5 weeks ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Nov 27, 2024, 7:00 AM EST - 7 weeks ago

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 6, 2024, 7:00 AM EST - 2 months ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2024, 3:31 PM EST - 2 months ago

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 7:00 AM EDT - 2 months ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 14, 2024, 4:58 PM EDT - 3 months ago

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Sep 13, 2024, 7:00 AM EDT - 4 months ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 6, 2024, 7:00 AM EDT - 4 months ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:10 PM EDT - 5 months ago

Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 11:13 PM EDT - 6 months ago

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 26, 2024, 8:00 AM EDT - 6 months ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

May 15, 2024, 8:08 AM EDT - 8 months ago

Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB

May 15, 2024, 7:00 AM EDT - 8 months ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 8, 2024, 7:00 AM EDT - 9 months ago

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 6, 2024, 11:44 AM EDT - 9 months ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 8:00 AM EDT - 9 months ago

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 2, 2024, 7:00 AM EDT - 9 months ago

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 26, 2024, 7:00 AM EDT - 9 months ago

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 22, 2024, 7:00 AM EDT - 9 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Apr 4, 2024, 7:00 AM EDT - 10 months ago

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Mar 14, 2024, 5:34 PM EDT - 11 months ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO MREO TAK WVE

Feb 28, 2024, 7:00 AM EST - 11 months ago

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 11:47 AM EST - 11 months ago

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 8:00 AM EST - 11 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 7:00 AM EST - 11 months ago

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Feb 13, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Feb 8, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Feb 1, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Dec 19, 2023, 7:00 AM EST - 1 year ago

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Dec 11, 2023, 1:03 AM EST - 1 year ago

Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects

Nov 27, 2023, 7:00 AM EST - 1 year ago

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

Nov 9, 2023, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

Nov 6, 2023, 11:43 AM EST - 1 year ago

Krystal Biotech Inc. (KRYS) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

Sep 28, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

Sep 22, 2023, 9:54 AM EDT - 1 year ago

Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement

Sep 21, 2023, 9:00 AM EDT - 1 year ago

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

Sep 7, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Aug 21, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

Aug 7, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

Jul 31, 2023, 10:26 PM EDT - 1 year ago

Krystal Biotech: Pioneering Rare Disease Gene Therapies

Jul 26, 2023, 4:14 PM EDT - 1 year ago

Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

Jul 3, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis

Jun 5, 2023, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences